Table 2.
Age at onset by genotype in LRRK2 p.G2019S carriers in this study
|
DNM3 rs2421947 | |||||||
|---|---|---|---|---|---|---|---|
| Population series | Mean age at onset (SD) |
ANOVA p value | GG vs. CG p valuea | CG vs. CC p valuea | GG vs. CC p valuea | ||
| GG | CG | CC | |||||
| Ashkenazi Jewish (n = 146) | 57.20 (8.96) | 60.11 (12.21) | 58.41 (8.01) | 0.34 | 0.13 | 0.45 | 0.58 |
| North African (n = 285) | 52.64 (11.21) | 51.95 (11.99) | 54.27 (11.05) | 0.49 | 0.65 | 0.23 | 0.40 |
| Europeanb (n = 277) | 63.26 (12.14) | 61.20 (12.45) | 62.17 (13.48) | 0.52 | 0.24 | 0.64 | 0.63 |
| Combine(dcn = 708) |
57.11 (12.02) |
57.44 (12.93) |
58.59 (12.30) |
0.55 |
0.76 |
0.37 |
0.28 |
|
VAMP4 rs11578699 | |||||||
| Population series |
CC |
TC |
TT |
ANOVA p value |
CC vs. TC p valuea |
TC vs. TT p valuea |
CC vs. TT p valuea |
| Ashkenazi Jewish (n = 24) | 63.92 (9.57) | 57.45 (11.93) | 57.00 (N/A) | 0.91 | 0.17 | N/A | N/A |
| North African (n = 484) | 54.38 (11.89) | 53.35 (11.58) | 55.22 (11.48) | 0.55 | 0.36 | 0.38 | 0.68 |
| Europeanb (n = 248) | 62.44 (12.38) | 63.89 (12.21) | 61.33 (13.75) | 0.66 | 0.41 | 0.55 | 0.79 |
| Combinedc (n = 756) | 57.39 (12.61) | 56.41 (12.62) | 56.76 (12.10) | 0.60 | 0.32 | 0.85 | 0.73 |
Combined subgroup mean and standard deviation age at onset in years of LRRK2 p.G2019S parkinsonism for DNM3 rs2421947 and VAMP4 rs11578699 genotypes; one-way ANOVA between DNM3 rs2421947 and VAMP4 rs11578699 genotypes; Student’s t-test between genotype.
Key: ANOVA, analysis of variance; DNM3, Dynamin 3; LRRK2, leucine-rich repeat kinase 2; N/A, not available; VAMP4, vesicle-associated membrane protein 4.
a
Uncorrect.
b
The following population series subgroups were from combined European unspecific and British.
c
The following population series subgroups were from combined Ashkenazi Jewish, North African, European unspecific, and British.